Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
Biohaven's Revenue Path: SCA And Obesity Therapies
05:30am, Friday, 29'th Nov 2024
Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treat
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
11:51am, Monday, 25'th Nov 2024
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:32am, Monday, 25'th Nov 2024
U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
07:45am, Monday, 25'th Nov 2024
Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve sta
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
07:30am, Monday, 25'th Nov 2024
In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
04:05pm, Tuesday, 12'th Nov 2024
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results from pivotal trial with troriluzole i
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
04:05pm, Wednesday, 02'nd Oct 2024
NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
06:00am, Tuesday, 01'st Oct 2024
NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
04:05pm, Monday, 30'th Sep 2024
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
07:30am, Monday, 30'th Sep 2024
Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melas
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
11:56am, Tuesday, 24'th Sep 2024
The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
10:42am, Tuesday, 24'th Sep 2024
Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinoc
Overlooked Stock: BHVN
05:02pm, Monday, 23'rd Sep 2024
Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
02:55pm, Monday, 23'rd Sep 2024
Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
02:40pm, Monday, 23'rd Sep 2024
Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.
